Samik Pharmaceutical (A014950) Stock Overview

Develops and manufactures pharmaceuticals. More details

A014950 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue grew by 7.5% over the past year

Risk Analysis

Does not have a meaningful market cap (₩90B)

A014950 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

View narrative

Lou_Basenese

Community Contributor

US$7.6FV • 76.3% undervalued

5022.2%Revenue growth p.a.

598

8d ago

Samik Pharmaceutical Company LTD. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Samik Pharmaceutical
Historical stock prices
Current Share Price	₩9,830.00
52 Week High	₩25,050.00
52 Week Low	₩6,650.00
Beta	0
1 Month Change	-16.98%
3 Month Change	-48.02%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.13%

Recent updates

Shareholder Returns

	A014950	KR Pharmaceuticals	KR Market
7D	-0.1%	-4.7%	8.3%
1Y	n/a	41.3%	130.0%

Return vs Industry: Insufficient data to determine how A014950 performed against the KR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how A014950 performed against the KR Market.

Price Volatility

Is A014950's price volatile compared to industry and market?
A014950 volatility
A014950 Average Weekly Movement	10.0%
Pharmaceuticals Industry Average Movement	7.4%
Market Average Movement	9.0%
10% most volatile stocks in KR Market	16.1%
10% least volatile stocks in KR Market	4.6%

Stable Share Price: A014950 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A014950's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1973	n/a	Choong-Hwan Lee	www.samik.co.kr

Samik Pharmaceutical Company LTD. develops and manufactures pharmaceuticals. The company offers oral therapeutic pharmaceuticals.

Samik Pharmaceutical Company LTD. Fundamentals Summary

How do Samik Pharmaceutical's earnings and revenue compare to its market cap?
A014950 fundamental statistics
Market cap	₩90.40b
Earnings (TTM)	-₩754.89m
Revenue (TTM)	₩60.02b

1.5x

P/S Ratio

-119.8x

P/E Ratio

Is A014950 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A014950 income statement (TTM)
Revenue	₩60.02b
Cost of Revenue	₩17.72b
Gross Profit	₩42.30b
Other Expenses	₩43.05b
Earnings	-₩754.89m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-82.09
Gross Margin	70.47%
Net Profit Margin	-1.26%
Debt/Equity Ratio	3.9%

How did A014950 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

n/a

Payout Ratio

Does A014950 pay a reliable dividends?

See A014950 dividend history and benchmarks

When do you need to buy A014950 by to receive an upcoming dividend?
Samik Pharmaceutical dividend dates
Ex Dividend Date	Dec 29 2025
Dividend Pay Date	Apr 20 2026
Days until Ex dividend	104 days
Days until Dividend pay date	8 days

Does A014950 pay a reliable dividends?

See A014950 dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/10 06:53
End of Day Share Price	2026/04/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Samik Pharmaceutical Company LTD. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Samik Pharmaceutical Company LTD.KOSDAQ:A014950 Stock Report